Q3 2025 Canopy Growth Corp Earnings Call Transcript
Key Points
- Canopy Growth Corp (CGC) reported a significant improvement in adjusted EBITDA loss, narrowing it by 61% compared to the previous year.
- The company achieved record revenue growth in its Canadian medical cannabis segment, with a 16% year-over-year increase.
- International markets, particularly in Europe, showed strong performance with a 14% increase in net revenue, driven by growth in Poland and Germany.
- The launch of the Claybourne brand in Canada was successful, quickly becoming the number three infused pre-roll in British Columbia and Ontario.
- Canopy Growth Corp (CGC) has made progress in reducing its term loan balance and improving its cash flow, with a 17% improvement in free cash flow compared to the previous year.
- Consolidated net revenue decreased by 5% compared to the previous year, indicating challenges in overall revenue growth.
- The gross margin declined to 32% from 36% a year ago, reflecting increased costs and competitive pressures.
- The adult-use cannabis business in Canada experienced a 10% year-over-year decline, despite a quarter-over-quarter improvement.
- Storz & Bickel's gross margin decreased to 41% from 51% last year, due to higher indirect costs including shipping.
- The path to full legalization in the US remains uncertain, posing a challenge for Canopy Growth Corp (CGC)'s expansion plans in the US market.
Good morning. My name is Joanna, and I will be your conference operator today. I would like to welcome you to Canopy Growth's third quarter, fiscal 2025 financial results conference call. Currently all participants are in a listen-only mode.
I'll now turn the call over to Tyler Burns, Director of Investor Relations. Tyler, you may begin the conference call.
Good morning and thank you for joining us on our call today. We have Canopy Growth's Chief Executive Officer Luc Mongeau; and Chief Financial Officer, Judy Hong; Before financial markets open today, Canopy Growth issued a news release announcing the financial results for our third quarter fiscal year 2025 ended December 31st 2024.
The news release and filed financial statements have been filed on EDGAR and CDAR and will be available on our website under the investors tab. Before we begin, I would like to remind you that our discussion during this call will include forward-looking statements that are based on management's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
